PT Etana Biotechnologies Indonesia

Established in 2014 by founder Nathan Tirtana, PT Etana Biotechnologies Indonesia (Etana) is a biopharmaceutical company focused on developing and commercializing biologic drugs for the Southeast Asian market. The company operates in research, development, manufacturing, and marketing of therapies for oncology, autoimmune disorders, metabolic diseases, and other life-threatening conditions. Etana's business model centers on making treatments more accessible and affordable through local production, aligning with Indonesian government health programs.

Etana has positioned itself in the region by becoming the first pharmaceutical entity in ASEAN with mRNA technology capabilities. This platform allows for rapid development of new vaccines and other biopharmaceutical products. A significant milestone was the inauguration of its biopharmaceutical factory in the Pulogadung Industrial Estate, East Jakarta, in October 2022, an event attended by the President of the Republic of Indonesia. This facility adheres to international Good Manufacturing Practices (cGMP) and has received halal certification, enabling the production of a wide range of biologic therapies. The company has received multiple rounds of funding from international investors, including DEG, Yunfeng Capital, HighLight Capital, and East Ventures, to expand its product pipeline and manufacturing capacity, particularly in oncology.

The company's product portfolio includes treatments for oncology, nephrology, vaccines, and metabolic conditions. Key products include a bevacizumab biosimilar (BEVAGEN), used for treating advanced non-small cell lung cancer and metastatic colorectal cancer, produced under license from Innovent Biologics. Etana also produces Erythropoietin (EPO), marketed as RENOGEN, for anemia associated with chronic kidney disease. In response to the global pandemic, Etana developed an mRNA COVID-19 vaccine, InaRNAVac, through a technology transfer collaboration with Chinese firms, which received an Emergency Use Authorization from Indonesia's food and drug authority (BPOM) and halal certification. The company is also expanding into other vaccine platforms, including adenovirus technology and a PCV-13 vaccine for pneumonia in children. Its strategic collaborations with international pharmaceutical companies and local academic institutions, such as Universitas Gadjah Mada (UGM), are central to its strategy of accelerating product development through technology transfer and joint research.

Keywords: biopharmaceutical, monoclonal antibodies, mRNA technology, vaccine production, oncology, biosimilars, Southeast Asia, pharmaceutical manufacturing, Erythropoietin (EPO), bevacizumab, local production, halal certified, drug development, nephrology treatments, clinical trials, technology transfer, cell therapy, gene therapy, biologics, pharmaceutical R&D, Indonesian healthcare